GSK (GSK)

NYSE: GSK · Real-Time Price · USD

38.78

-1.07 (-2.69%)

At close: May 01, 2025, 12:07 PM

-2.69% (1D)

Bid	38.76
Market Cap	78.57B
Revenue (ttm)	31.38B
Net Income (ttm)	2.58B
EPS (ttm)	1.67
PE Ratio (ttm)	23.22
Forward PE	9.21
Analyst	Hold

Ask	38.82
Volume	2,195,477
Avg. Volume (20D)	5,708,763
Open	39.42
Previous Close	39.85
Day's Range	38.77 - 39.42
52-Week Range	31.72 - 45.93
Beta	0.30

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines ...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Mar 28, 1980

Employees 68,629

Stock Exchange NYSE

Ticker Symbol GSK

Website https://www.gsk.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for GSK stock is "Hold." The 12-month stock price forecast is $47, which is an increase of 21.20% from the latest price.

Stock Forecasts

Earnings Surprise

New

GSK has released their quartely earnings on Apr 30, 2025:

Revenue of $9.46B exceeds estimates by $2B, with 1.32% YoY growth.

EPS of 1.13 exceeds estimates by 0.09, with 3.39% YoY growth.

Why Price Moved

1 day ago New

+2.26%

GSK shares are trading higher after the company re... Unlock content with Pro Subscription

2 months ago

+8.21%

GSK shares are trading higher after the company reported better-than-expected Q4 financial results.

News

Just now · zacks.com

Here's Why GSK (GSK) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 day ago · zacks.com

GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance

GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.

1 day ago · seekingalpha.com

GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript

GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown -...

17 hours ago · zacks.com

Here's Why GSK (GSK) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

18 hours ago · benzinga.com

Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales

On Wednesday, British multinational pharmaceutical GSK Plc GSK reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts ...

19 hours ago · investors.com

GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate Tariffs

GSK stock jumped early Wednesday after the drugmaker reported adjusted earnings of $1.20 per share on $10.06 billion in first-quarter sales.

19 hours ago · investopedia.com

GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs

U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the...

19 hours ago · proactiveinvestors.co.uk

GSK: Disproportionately discounted, but earnings beat shows signs of reappraisal

Shore Capital is sticking with its upbeat view on GSK PLC (LSE:GSK, NYSE:GSK), calling the stock “disproportionately discounted” after first-quarter numbers surpassed expectations and guidance was hel...

20 hours ago · zacks.com

GSK (GSK) Q1 Earnings Surpass Estimates

GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago.

21 hours ago · proactiveinvestors.co.uk

GSK jumps 4% as earnings beat boosts confidence

GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% on Tuesday, adding £2.6 billion to its market value, after the drugmaker delivered better-than-expected first-quarter results and reiterated full-year guidan...

Load More News